Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ORM 5029

Next Previous
X
Search
Drug Profile

ORM 5029

Alternative Names: ORM-5029

Latest Information Update: 21 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orum Therapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Peptide-chain-release factor 3 degraders; Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HER2 positive breast cancer
  • Preclinical Solid tumours

Most Recent Events

  • 18 Apr 2023 Pharmacodynamics data from a phase I trial in HER2-positive breast cancer released by Orum Therapeutics
  • 03 Oct 2022 Phase-I clinical trials in HER2-positive breast cancer (Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion) (NCT05511844)
  • 23 Aug 2022 Orum Therapeutics plans a phase I trial for Solid tumours (Late-stage disease) in USA (IV, Infusion), in October 2022 (NCT05511844)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top